A toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis

Journal of Investigative Dermatology

Volumn 133, Issue 7, 2013, Pages 1777-1784

  Jiang, Weiwen ^a   Zhu, Fu Gang ^a   Bhagat, Lakshmi ^a   Yu, Dong ^a   Tang, Jimmy X ^a   Kandimalla, Ekambar R ^a   La Monica, Nicola ^a   Agrawal, Sudhir ^a  

^a HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 23; PEPTIDES AND PROTEINS; PROTEIN AIM2; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 ANTAGONIST; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 8 ANTAGONIST; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EAR; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; SKIN DEFECT; TH1 CELL; TH17 CELL;

EID: 84879410185     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.57     Document Type: Article

References (47)

1. Azfar RS, Gelfand JM (2008) Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 20:416-22
2. Barrat FJ, Meeker T, Chan JH et al. (2007) Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 37:1-5
3. Bauernfeind FG, Horvath G, Stutz A et al. (2012) Cutting edge: NF-kB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 183:787-91
4. Chan JR, Blumenschein W, Murphy E et al. (2006) IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 203:2577-87 (Pubitemid 44833335)
5. Chamian F, Lowers MA, Lin S et al. (2005) Alefacept reduces infiltrating T cells, activated dendritic cells and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 102:2075-80 (Pubitemid 40262014)
6. Christensen SR, Shupe J, Nickerson K et al. (2006) Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25:417-28 (Pubitemid 44354217)
7. Davidovici BB, Sattar N, Prinz JC et al. (2010) Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 130:1785-96
8. Christophers E (2001) Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 26:314-20
9. Demaria O, Pagni PP, Traub S et al. (2010) TLR8 deficiency leads to autoimmunity in mice. J Clin Invest 120:3651-62
10. Dombrowski Y, Peric M, Koglin S et al. (2011) Cytoloslic DNA triggers inflammasomes activation in keratinocytes in psoriatic lesions. Sci Transl Med 3:82ra38
11. Di Cesare A, Di Meglio P, Nestle FO (2009) The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129:1339-50
12. Dong L, Ito S, Ishii KJ et al. (2004) Suppressive oligonucleotides protect against the development of collagen-induced arthritis in mice. Arthritis Rheum 50:1686-9 (Pubitemid 38608092)
13. Fujimoto C, Klinman DM, Shi G et al. (2009) A suppressive oligodeoxynucleo-tide inhibits ocular inflammation. Clin Exp Immunol 156:528-34
14. Farkas A, Kemény L (2012) Monocyte-derived interferon-alpha primed dendritic cells in the pathogenesis of psoriasis: new pieces in the puzzle. Int Immunopharmacol 13: 215-8
15. Ganguly D, Chamilos G, Lande R et al. (2009) Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 206:1983-94
16. Hari A, Flach TL, Shi Y et al. (2010) Toll-like receptors: role in dermatological disease. Mediators Inflamm 2010:437246
17. Gelfand JM, Neimann AL, Shin DB et al. (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735-41 (Pubitemid 44547793)
18. Heidrick MN, Lonsdorf AS, Shirakawa AK et al. (2009) CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest 119:2317-9
19. Johnson-Huang LM, Lowes MA, Krueger JG (2012) Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech 5:423-33
20. Ho PP, Fontoura P, Ruiz PJ et al. (2003) An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J Immunol 171:4920-6 (Pubitemid 37310616)
21. Kandimalla ER, Bhagat L, Wang D et al. (2013) Synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res; e-pub ahead of print 8 February 2013
22. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:373-84
23. Laws PM, Young HS (2012) Current and emerging systemic treatment strategies for psoriasis. Drugs 72:1867-80
24. Lande R, Gregorio J, Facchinetti V et al. (2007) Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449:564-9 (Pubitemid 47525141)
25. Lenert P (2010) Nucleic acid sensing receptors in systemic lupus erythemato-sus: development of novel DNA-and/or RNA-like analogues for treating lupus. Clin Exp Immunol 161:208-2
26. Madsen P, Rasmussen HH, Leffers H et al. (1991) Molecular cloning, occurrence and expression of a novel partially secreted protein ''psoriasin'' that is highly up-regulated in psoriatic skin. J Invest Dermatol 97:701-12
27. Lowes MA, Chamian F, Abello MV et al. (2005) Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 102:10957-62
28. Mehta NN, Azfar RS, Shin DB et al. (2010) Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 31:1000-6
29. Morizane S, Yamasaki K, Muhleisen B et al. (2012) Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol 132:135-43
30. Mills KHG, Dunne A (2009) IL-1, master mediator or initiator of inflammation. Nat Med 15:1363-4
31. Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361:496-509
32. Nickoloff BJ, Nestle FO (2004) Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 113:1664-75 (Pubitemid 39071656)
33. Nickerson KM, Christensen SR, Shupe J et al. (2010) TLR9 regulates TLR7-and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol 184:1840-8
34. Nijsten T, Stern RS (2012) How epidemiology has contributed to a better understanding of skin disease? J Invest Dermatol 132:994-1002
35. Rizzo HL, Kagami S, Phillips KG et al. (2011) IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol 186:1495-502
36. Patel U, Mark NM, Machler BC et al. (2011) Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism. Br J Dermatol 164:670-2
37. Sarvestani ST, Williams BRG, Gantier MP (2012) Human Toll-like receptor 8 can be cool too: implications for foreign RNA sensing. J Inteferon Cytokine Res 32:350-61
38. Sims JE, Smith DE (2010) The IL-1 family: regulators of immunity. Nat Rev Immunol 10:89-102
39. Schroder K, Tschopp J (2010) The inflammasomes. Cell 140:821-32
40. Suárez-Fariñas M, Li K, Fuentes-Duculan J et al. (2012) Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol 132: 2552-64
41. Wang D, Bhagat L, Yu D et al. (2009) Oligodeoxyribonucleotide-Based Antagonists for Toll-Like Receptors 7 and 9. J Med Chem 52:551-8
42. van der Fits L, Mourits S, Voerman JS et al. (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182:5836-45
43. Yu D, Wang D, Zhu FG et al. (2009) Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9. J Med Chem 52:5108-14
44. Zeuner RA, Ishii KJ, Lizak MJ et al. (2002) Reduction of CpG-induced arthritis by suppressive oligonucleotides. Arthritis Rheum 46:2219-4
45. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ et al. (2009) Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myloid dendritic cells. J Invest Dermatol 129:79-88
46. Zibert JR, Skov L, Thyssen JP et al. (2010) Significance of the S100A4 protein in psoriasis. J Invest Dermatol 130:150-60
47. Zheng YD, Danilenko DM, Valdez P et al. (2007) Interleukin (IL)-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445:648-51 (Pubitemid 46232884)